Research in contextEvidence before this studyThis study addresses changes in peripheral blood lymphocyte counts and subset composition in COVID-19 patients. Based on our PubMed search (without language restriction) on March 25, 2020, using "COVID-19″ AND "T cell response" as well as "COVID-19″ AND "T cell" AND "recover\*" OR "convalesc\*" OR "improv\*" as search criteria, we identified only one preliminary report coming from Wuhan, China. This article however, does neither display the way in which the data was obtained nor does it report longitudinal changes in individual patients. Thus, to our knowledge, to date there are no studies involving longitudinal monitoring of neither T cell responses nor those employing Good Laboratory Practice (GLP)-conforming analysis of different lymphocyte subsets in COVID-19 patients.Added value of this studyHere we used GLP-conforming flow cytometry with certified counting beads to investigate longitudinal changes in several major lymphocyte subsets in patients with mild and severe COVID-19. Furthermore, we report on changes of T cell activation phenotype and its correlation to clearance of the disease. Here we present the first comprehensive analysis of innate and adaptive lymphocyte dynamics in COVID-19 with regard to carefully selected age- and gender-matched controls. Our data report a link of T cell memory formation and clearance of SARS-CoV-2 infection and warrants further research.Implications of all the available evidenceIn the present study we shed light on immune cells involved in clearing SARS-CoV-2 infection. Adding comprehensive lymphocyte analysis to current practice may offer prognostic value as biomarker for disease outcome and control.Alt-text: Unlabelled box

1. Introduction {#sec0004}
===============

Cross-species infections are becoming more common due to increase in interlinking human and animal activities, furthered by great genetic diversity of viruses [@bib0001]. The threat of emerging global pandemics by new virus species and/or mutants has been significantly heightened in the wake of severe acute respiratory syndrome coronavirus (SARS-CoV) [@bib0002] and Middle East respiratory syndrome coronavirus (MERS-CoV) [@bib0003] outbreaks. Both of these zoonotic coronaviruses are highly infectious and have high fatality rates [@bib0004]. In December 2019, another type of coronavirus, later named SARS-CoV-2, was reported in patients with pneumonia, causing coronavirus disease 2019 (COVID-19) [@bib0005]. SARS-CoV-2 has since turned into a global pandemic with a total of 9 110 186 confirmed cases of COVID-19 and 473 061 fatal cases as of June 24th 2020 according to recent WHO situation report [@bib0006].

Since the onset of the SARS-CoV-2 pandemic, research focuses on immune profiling of the infection, striving towards better patient management and treatment. As it is the case in the majority of viral infections, key players in battling the SARS-CoV-2 appear to be NK, T and B cells \[[@bib0007],[@bib0008]\]. According to available data [@bib0009], [@bib0010], [@bib0011], [@bib0012], COVID-19 patients with severe disease have increased levels of C-reactive protein and IL-6 as well as augmented neutrophil counts but reduced lymphocyte counts in blood. Moreover, NK cells and CD8^+^ *T* cells in COVID-19 patients appear to be functionally exhausted, indicated by increased expression of NKG2A [@bib0008] and lower production of IFN-γ, TNF-α and IL-2 [@bib0013]. Nevertheless, it is unclear whether and how profiling of T cell responses can be used as prognostic biomarker for disease outcome and control. Furthermore, no data is available on the role of γδ T cells in anti-SARS-CoV-2 immune responses, although it has been demonstrated that these cells contribute to immunity against SARS-CoV and other viruses [@bib0014], [@bib0015], [@bib0016].

In the present study we analysed dynamics of NK, NKT, αβ and γδ T cells subsets in the peripheral blood of patients with mild and severe COVID-19 compared to gender- and age-matched controls. To reliably assess major lymphocyte subsets' profiles during successful immune response against SARS-CoV-2 infection, we developed two comprehensive Good Laboratory Practice (GLP)-conforming 11-colour flow cytometric panels approved for clinical diagnostics. Using those panels, we examined the composition of seven major lymphocyte populations in patients with mild and severe COVID-19 and followed formation of effector and memory αβ and γδ T cells from consecutive blood samples of patients who did or did not clinically improve. We found that recovery from COVID-19 was closely associated with expansion and differentiation/maturation in αβ, but not γδ T cells.

2. Materials and methods {#sec0005}
========================

2.1. Study participants {#sec0006}
-----------------------

Patients with PCR-confirmed SARS-CoV-2 infection were recruited at Hannover Medical School from March 30th until April 16th 2020. Based on the clinical presentation, disease was classified as "mild" or "severe" for every single patient at admission. Mild disease was defined for patients with stable lung parameters with no oxygen flow or of up to 3 litres per minute. In contrast, severe disease was defined as oxygen flow equal or greater than 6 litres per minute to maintain a SpO~2~ \> 90%, or non-invasive or invasive ventilation. Patient characteristics are shown in [Table 1](#tbl0001){ref-type="table"}. To assess the impact of infection on lymphocyte subsets, age- and gender-matched healthy controls (HC) were selected for every patient in a 2:1 control-to-patient ratio. Those patients of 56 years of age and older were gender-matched to the group of 56--69 year old healthy controls. Healthy controls were recruited through the Institute of Transfusion Medicine in October and November 2019, prior to SARS-CoV-2 outbreak. Healthy control characteristics are listed in [Supplementary Table 1](#sec0018){ref-type="fn"}. The study was approved by the institutional review board at Hannover Medical School (\#9001_BO_K2020 and \#8606_BO_K2019) and informed consent was obtained from all patients and healthy controls.Table 1Patients' characteristics.Table 1:IDSeverityAgeGenderPEMCcv PEMCSymptomsFirst Sampling[\*](#tb1fn1){ref-type="table-fn"}Con-valescenceConvalescence Sampling[\*](#tb1fn1){ref-type="table-fn"}001mild71mnonoFever, malaise13NANA002mild68myesyesFever, diarrhoea13NANA003mild64myesyesMalaise14NANA012mild48fyesnoFever, dry cough, dyspnoea8NANA013mild85myesyesFever, dry cough4yes17014mild51myesyesFever, myalgia16NANA016mild91myesyesDry cough, malaise9no12019mild48fyesnoDry cough9NANA020mild57fyesyesDyspnoea, myalgia, diarrhoea, emesis8NANA021mild48myesyesFever, dry cough, myalgia3NANA022mild75myesyesFever8no18023mild60myesyesDry cough, myalgia, cephalgia10NANA027mild83fyesyesFever, dry cough, dyspnoea, malaise5yes12028mild42myesnoNausea, emesis3NANA031mild79myesyesDiarrhoea, nausea, emesis2no7004severe75fyesyesFever, dry cough, dyspnoea7yes17005severe60myesyesFever, dry cough20NANA006severe51myesnoFever, diarrhoea, nausea12yes19007severe60myesnoFever, dry cough, diarrhoea16no33008severe56myesyesFever, dry cough, dyspnoea19no26009severe68myesnoDry cough, diarrhoea18yes25010severe69myesyesDry cough, dyspnoea21no38011severe45myesyesDry cough, dyspnoea5no12015severe47myesyesFever, dry cough, dyspnoea16no31017severe19myesnoMalaise5yes19018severe82fyesyesDry cough7NANA025severe65myesyesFever, dry cough, dyspnoea8yes16026severe71myesyesFever, dry cough13no18029severe53myesnoFever, dry cough, diarrhoea, nausea8no15030severe39mnonoFever, dyspnoea32NANA[^2][^3]

2.2. Flow cytometry {#sec0007}
-------------------

EDTA-anticoagulated whole blood was stained with the antibodies as listed in [Supplementary Table 2](#sec0018){ref-type="fn"}. For analysis of absolute cell counts BD TruCount™ tubes were used, and cells were analysed in a lyse-no-wash fashion according to manufacturer\'s instructions. For analysis of activation markers, cells were analysed in a lyse-wash fashion. Stained cells were acquired on BD FACS Lyric, standardized for clinical cell analysis. Flow cytometry data were analysed using FCSExpress 7 (De Novo Software).

2.3. Statistical analysis {#sec0008}
-------------------------

Data were analysed using Prism 7.05 (GraphPad). Patient groups were pairwise compared either to each other or to the reference group of healthy controls. Where data was normally distributed, unpaired t-test was used and where that was not the case, Mann-Whitney U test was applied. For categorical variables Fisher\`s exact test was used. For analysis of longitudinal changes two-tailed paired t-test was applied.

3. Results {#sec0009}
==========

Our cohort of 30 hospitalized COVID-19 patients was predominantly male (80%), of older age (mean 61 years, range 19--91) and 93% had mostly mild pre-existing medical conditions. Patients were classified upon admission as mild (*n* = 15) and as severe (*n* = 15, [Table 1](#tbl0001){ref-type="table"}). Patients with severe disease (SD) were slightly older and had a higher proportion of male gender, although both not significantly different from patients with mild disease (MD). Representative of the wider population [@bib0017], almost all (28/30) patients in our cohort had pre-existing medical conditions. Characteristics of healthy controls (HC) are listed in [Supplementary Table 1](#sec0018){ref-type="fn"}.

3.1. Severe COVID-19 patients show reduced counts of lymphocyte subsets {#sec0010}
-----------------------------------------------------------------------

Using BD TruCount™ technology, we observed significantly reduced lymphocyte numbers in COVID-19 patients, inversely correlated with disease severity ([Supplementary Fig. 1](#sec0018){ref-type="fn"}).

To further characterize the composition of the lymphocyte pool, we developed two comprehensive GLP-conforming 11-colour comprehensive flow cytometric mAb panels, which were approved in-house for clinical diagnostics. The first panel of mAb used in this study ([Supplementary Fig. 2a](#sec0018){ref-type="fn"}) allowed us to profile NK, NKT, B, αβ and γδ T cell numbers in blood of HC and COVID-19 patients with MD or SD. Compared to MD patients, we found strikingly lower numbers of NK, NKT, γδ-, and CD8^+^ cells in the blood of SD COVID-19 patients ([Fig. 1](#fig0001){ref-type="fig"}). γδ^+^Vγ9^+^ cells are reported to be responsive to phospho-antigens \[[@bib0018],[@bib0019]\] and we noticed a trend to reduced numbers of γδ^+^Vγ9^+^ in SD patients compared to MD (*P* = 0.0502, two-tailed Student\'s t-test), going in hand with recently published data [@bib0020]. In addition, all subsets investigated were significantly reduced in SD patients compared to HC ([Fig. 1](#fig0001){ref-type="fig"}). Interestingly, MD patients had similar levels of NK, NKT, γδ-, conventional CD4^+^ (CD4~conv~) and CD8^+^ cells as compared to HC. Of note, both MD and SD patients showed a marked reduction of regulatory T cells ([Fig. 1](#fig0001){ref-type="fig"}). Together, these data provide a detailed depiction of reduced lymphocyte subsets in mild and severe COVID-19 patients, employing certified counting beads for analysis of absolute cell numbers.Fig. 1Absolute numbers of lymphocyte subsets in healthy controls and mild and severe COVID-19 patients.Lines represent median. Statistical analysis was performed by Mann-Whitney *U* test or Student\'s t-test where applicable. \**p*\< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001; ns: not significant; HC: Healthy Control; MD: Mild Disease; SD: Severe Disease.Fig 1

3.2. Patients with severe COVID-19 infection lack generation of effector and central memory αβ CD4~conv~ and CD8^+^ cells {#sec0011}
-------------------------------------------------------------------------------------------------------------------------

To characterize the involvement of different subsets of αβ CD4~conv~, αβ CD8^+^, and γδ T cells based on their antigen experience \[[@bib0021],[@bib0022]\], we developed a staining panel dedicated to identifying four distinct populations based on CD62L and CD45RA expression ([Supplementary Fig. 2b](#sec0018){ref-type="fn"}). Looking at the distribution of CD45RA^+^CD62L^+^ on conventional CD4^+^ *T* cells (CD4~conv~) we defined naïve (CD4~naïve~, CD45RA^+^CD62L^+^), effector/effector memory (CD4~eff/em~, CD45RA^−^CD62L^−^), terminally differentiated cells (CD4~temra~, CD45RA^+^CD62L^−^) and central memory (CD4~cm~, CD45RA^−^CD62L^+^). Based on this allocation, we observed a marked decrease of CD4~eff/em~ in SD compared to MD patients ([Fig. 2](#fig0002){ref-type="fig"}a). In addition, both COVID-19 groups had increased frequencies of CD4~temra~ and decreased CD4~eff/em~ compared to HC ([Fig. 2](#fig0002){ref-type="fig"}a). The same observations were made when absolute cell counts were calculated ([Supplementary Fig. 3a](#sec0018){ref-type="fn"}). Investigating the memory phenotypes of αβ CD8^+^ cells revealed a striking increase in frequencies of CD8~eff/em~ cells, as well as a decrease of CD8~naïve~ T cells in MD compared to HC and SD ([Fig. 2](#fig0002){ref-type="fig"}b). These observations indicate successful mobilization and/or differentiation of cytotoxic lymphocytes (CTL) in MD patients. Compared to MD, patients with SD had higher frequency of CD8~naïve~ T cells and lower frequency of CD8~eff/em~ cells, implying deficits in successfully mounting CTL responses in SD patients or increased recruitment to the peripheral organs. Furthermore, we found similar frequencies of CD8~cm~ and CD8~temra~ in samples from MD and HC but a decrease of these cell populations in SD ([Fig. 2](#fig0002){ref-type="fig"}b), again hinting towards an impaired CTL response in patients with SD. The absolute numbers of CD8 memory subsets was changed similarly with the exception of CD8~naïve~ T cells in SD which were similar to those of MD patients ([Supplementary Fig. 3b](#sec0018){ref-type="fn"}).Fig. 2Mild COVID-19 disease is paralleled by increased levels of effector and memory T cells.Gated on CD4~conv~ (a). Gated on CD8^+^*T* cells (b). Lines represent median. Statistical analysis was performed by Mann-Whitney *U* test or Student\'s t-test where applicable.\**p*\< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001; ns: not significant; HC: Healthy Control. MD: Mild Disease; SD: Severe Disease.Fig 2

3.3. γδ T cells from COVID-19 patients exhibit a distinct memory signature {#sec0012}
--------------------------------------------------------------------------

Human γδ T cells have been shown to be important for regulating immune responses to CMV, HCV and SARS-CoV infections [@bib0014], [@bib0015], [@bib0016]. Using a panel of 11 specific mAb ([Supplementary Fig. 2b](#sec0018){ref-type="fn"}), we found that expression of CD45RA and CD62L on γδ cells would also allow their categorization into four subsets as defined above for αβ T cells. Interestingly, we revealed a marked increase in both frequencies and absolute cell numbers of naïve-like γδ (γδ~naïve-l~) cells, and a proportional decrease in effector-like γδ (γδ~eff-l~) cells in both groups of patients suffering from COVID-19 ([Fig. 3](#fig0003){ref-type="fig"}). These data suggest that γδ~eff-l~ T cells might be recruited from the blood to peripheral organs such as the lungs of COVID-19 patients and that these cells might participate in the immune response against SARS-CoV-2 infection.Fig. 3γδ T cells from COVID-19 patients exhibit a distinct memory signature.Gated on γδ T cells (a). Absolute numbers of γδ T cell subpopulations (b). Lines represent median. Statistical analysis was performed by Mann-Whitney *U* test or Student\'s t-test where applicable. \**p*\< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001; HC: Healthy Control. MD: Mild Disease; SD: Severe Disease.Fig 3

3.4. Early establishment of T cell memory suggests better clinical outcome {#sec0013}
--------------------------------------------------------------------------

To evaluate the hypothesis that convalescence from COVID-19 is related to establishment of successful T cell immunity, we evaluated the signature of CD4~conv~ and CD8^+^ cells based on the clinical course of the disease. To that end, we collected longitudinal samples of 5 MD and 12 SD patients. We defined convalescence as an improvement of lung function (e.g. reduction of oxygen flow or ventilation parameters), excluding transient variations, thus only taking long-lasting clinical improvement in consideration. Convalescence rate in MD and SD patients occurred at similar frequencies (2/5 vs 5/12) while the period of follow-up was slightly longer in SD patients without reaching statistical significance (SD: 10.08 vs MD: 7.60 days; [Table 1](#tbl0001){ref-type="table"}). To analyse the immune responses in a longitudinal manner, we selected convalescing (*n* = 7) and non-convalescing (*n* = 10) MD and SD patients. In all convalescing patients irrespective of the disease severity, we observed a strong decrease of the frequency of CD4~naïve~ and a marked increase of CD4~eff/em~ and CD4~cm~ populations ([Fig. 4](#fig0004){ref-type="fig"}a) suggesting a turnover of naïve to memory/effector cells. The same observations were made for all convalescing patients regarding the relative distribution of naïve and memory CD8^+^ *T* cell subsets ([Fig. 4](#fig0004){ref-type="fig"}b). Notably, no significant changes could be observed for any of the CD4~conv~ and CD8^+^ subpopulations in non-convalescing patients ([Fig. 4](#fig0004){ref-type="fig"}). We also failed to observe any significant alterations in frequencies of the different subtypes of γδ cells in relation to disease clearance ([Supplementary Fig. 4](#sec0018){ref-type="fn"}). We therefore suggest that the alterations observed for CD4~conv~ and CD8^+^ αβ T cells in convalescing patients that recover from COVID-19 are linked to differentiation of effector/memory αβ T cells.Fig. 4Increase of effector/memory T cells suggests better clinical outcome.Gated on CD4~conv~ (a). Gated on CD8^+^ (b). Graphs show patients' memory subsets' values in convalescing vs non-convalescing patients. Patients who were diagnosed with MD at the point of admission are displayed with blue lines. Patients with SD at the point of admission are depicted with red lines. Statistical analysis was performed paired Student\'s t-test. \**p*\< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001; ns: not significant.Fig 4

4. Discussion {#sec0014}
=============

From an immunological perspective, adaptive anti-viral responses occur in two layers. First, a NK, NKT and CD8^+^ *T* cell response is programmed to prevent the disease to proceed to a severe phase. Second, helper T cells are poised to influence and program B cells for specific neutralizing antibody formation, conferring long-lasting humoral immunity [@bib0023]. The establishment of immunity to SARS-CoV-2 has been associated with the presence of neutralizing IgG antibodies in blood sera \[[@bib0024],[@bib0025]\]. However, some viruses such as influenza are notoriously known to be resilient to establish humoral immunity [@bib0026]. This might also be the case for SARS-CoV-2. We therefore studied changes in T cell subsets in COVID-19 patients.

Applying two comprehensive GLP-conforming 11-colour flow cytometric panels approved for clinical diagnostics, this prospective single-centre study from Germany identified profound changes in absolute numbers in seven different lymphocyte subsets in hospitalized COVID-19 patients with mild and severe disease. These findings were in line with and extended the current literature on COVID-19-induced lymphocytopenia [@bib0009], [@bib0010], [@bib0011], [@bib0012]. Additionally, we revealed changes in the formation of different T memory cell subsets comparing mildly and severely affected COVID-19 patients with healthy controls. Moreover, in a longitudinal approach we showed that convalescing -- but not non-convalescing -- patients develop increased frequencies of different subsets of CD4~conv~ and CD8^+^T cell showing memory/effector phenotypes. Together, our findings indicate that mounting an efficient T cell response allows hospitalized patients to combat and overcome SARS-CoV-2 infections.

In agreement with recent reports, we observed a general decrease of lymphocytes in all COVID-19 patients that was more pronounced in severe cases \[[@bib0008], [@bib0009], [@bib0010],[@bib0012]\]. Such a reduction of immune cells in the blood of SD patients might be due to several causes. It is conceivable that infection with SARS-CoV-2 directly affects differentiation and/or production in and release from primary lymphoid organs. Although this virus in general is not suspected to infect and destroy immune cells or their progenitors to a large degree, it seems possible that such effects might be secondary and caused by massive release in inflammatory mediators as a response to the infection \[[@bib0009],[@bib0010]\]. Alternatively, failure to observe lymphocytes in the blood might be due to their homing/recruitment to the lung or other infected organs [@bib0011]. COVID-19 patients with a mild clinical course did not show reduction in NK, NKT and γδ T cells counts. NK cells are part of the innate immunity and their significance in clearance of viral infections has been well documented \[[@bib0027],[@bib0028]\]. It is thus reasonable to assume that these cells contribute to keeping the disease from progressing, as suggested before [@bib0008]. The observation that these innate and innate-like immune cells are present in regular numbers at early stages of the disease might also indicate that this arm of the immune system helps to contain early virus infection.

Compared to HC, COVID-19 patients showed already altered effector/effector memory and naïve T cell proportions at hospital admission. Increased frequencies of effector and memory populations in MD, but not SD, suggest that MD patients already launched a broad adaptive immune response at that time point, whilst this was presumably not the case in severely affected patients. Along the same line, a shift towards further activation of αβ T cells coincided with convalescence, also hinting at the presence of SARS-CoV-2 responsive T cells within this pool. These findings are in line with very recent reports describing the role of T cell immunity in COVID-19 patients [@bib0029], [@bib0030], [@bib0031], [@bib0032].

Data of the present study highlight the role of T cells in successfully controlling SARS-CoV-2 infections. Different sampling times of follow-up samples, as well as relatively small patient sample size remain the main limitation of this study. Additionally, combination of these highly standardized data with more in-depth analysis of SARS-CoV-2 specific responses might provide a more comprehensive overview of immune responses in COVID-19. Along those lines, a long-term longitudinal evaluation of a variety of immune subsets as recently reported in a pre-published study [@bib0033] would be of great value in our understanding of dynamics of anti-SARS-CoV-2 responses. More research is warranted, preferably in larger number of patients to corroborate findings of this study. Such research might also reveal implications for vaccine design and assessment of successful immune response in vaccine trials. Furthermore, standardized comprehensive lymphocyte subset analyses by flow cytometry can be easily implemented and, after stringent validation might serve as a biomarker for disease outcome and control.
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